Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Wallbridge Mining Company Limited (TSX: WM) (OTCQB: WLBMF) ("Wallbridge" or the "Company") is pleased to announce that it has closed its previously announced best efforts, public offering (the “Offering”) of (i) 65,000,000 Charity Flow-Through Units (the “Charity Flow-Through Units”) at a price of C$0.15 per Charity Flow-Through Unit, (ii) 49,000,000 Hard Dollar Units (the “Hard ...

RIYADH, Oct. 31, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), the RedAI trading platform used by Fast Moving Consumer Goods (‘FMCG’) businesses, announced the outcome of the Future Investment Initiative (FII9) in Riyadh, Saudi Arabia, where it held a formal signing ceremony to seal its landmark joint venture agreement with Kayanat Holding, and held more than one hundred meetings as part of preparations for Saudi launch. The formal signing ceremony, live on day ...

GEELONG, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the “Company”), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached agreement with Orion Infrastructure Capital (“OIC”) to provide a further up to US$7 million of funding. The Company also reports the cancellation of two electric vehicle (“EV”) wheel programs, which is consistent with the weakening of demand a ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that it has closed its previously-announced bought deal private placement pursuant to which NexGold issued 69,445,000 units of the Company (the “Units”) at a price of C$1.44 per Unit for aggregate gross proceeds of C$100,000,800, and 7,944,000 flow-through shares (the “ ...

BROAD ARROW, A HAGERTY COMPANY, ESTABLISHES EXCLUSIVE NORTHEAST PRESENCE AS AUDRAIN SOLIDIFIES POSITION AS REGION'S PREMIER AUTOMOTIVE DESTINATION A snapshot of the 2025 Audrain Newport Concours, which will feature Broad Arrow as exclusive auction partner beginning in 2026. Credit - Francesca Dolnier / Courtesy of Audrain Newport Concours & Motor Week A snapshot of the 2025 Audrain Newport Concours, which will feature Broad Arrow as exclusive auction partner beginning in 2026. Credit - Francesca Dolni ...

Core Insights - Capricor Therapeutics will release its financial results for Q3 2025 on November 10, 2025, followed by a conference call at 4:30 p.m. ET [1] - The company is focused on developing cell and exosome-based therapeutics for rare diseases, with its lead product candidate being Deramiocel for Duchenne muscular dystrophy (DMD) [2] Company Overview - Capricor Therapeutics is dedicated to advancing transformative therapies, particularly through its lead candidate Deramiocel, which is in late-stage clinical development for DMD [2] - Deramiocel has shown potent immunomodulatory and anti-fibrotic effects in preserving cardiac and skeletal muscle function in DMD patients [2] - The company is also utilizing its proprietary StealthX™ platform for the targeted delivery of therapeutics, with applications in vaccinology and treatment of various diseases [2] Recent Developments - Capricor has entered into an exclusive commercialization agreement for Deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [5]

Core Insights - Eos Energy Enterprises and Frontier Power Ltd. have announced a strategic order for 228 MWh of Eos Z3™ energy storage systems, marking a significant milestone in their partnership aimed at enhancing grid reliability through long-duration energy storage solutions [1][2][3] Partnership and Order Details - The 228 MWh order is the first to be executed under a previously established 5 GWh framework agreement, indicating a strong commitment to scaling alternative energy storage solutions [2] - This partnership is focused on deploying long-duration energy storage systems to support grid reliability across various markets, showcasing the readiness of Eos' technology for large-scale applications [2][3] Technology and Market Demand - Eos' Z3™ technology utilizes proprietary battery management systems and analytics platforms, which will be validated in diverse grid environments as part of Frontier's upcoming projects [3] - Frontier has advanced 11 GWh of long-duration storage projects to the second round of Ofgem's Cap-and-Floor program, all incorporating Eos' technology, reflecting a growing market demand for energy storage solutions that can provide over 8 hours of storage [4] Strategic Vision - The partnership aims to build a scalable platform for long-duration storage, emphasizing the innovative and sustainable nature of Eos' zinc technology, which is designed to support renewable energy growth and provide reliable power for future grid needs [5] - Eos' technology is characterized by enhanced energy density and safety, making it suitable for utility-scale applications and addressing the increasing complexity of grid demands [7]

On 31 October 2025 the Annual General Meeting of Shareholders of AB Akola Group approved the consolidated and the Company’s Financial Statements, consolidated Management Report, the Independent Practitioners’ Limited Assurance Report on AB Akola Group consolidated Sustainability Report, and Independent Auditor's Report on the Company’s consolidated Financial Statements for the financial year ended 30 June 2025. Key financial indicators Consolidated revenues of the subsidiaries of AB Akola Group (the Group) ...

Core Insights - Myriad Genetics announced that treatment informed by the GeneSight test resulted in faster initial remission and response in patients with Major Depressive Disorder (MDD), with benefits persisting over six months [1][2][3] Group 1: Study Overview - The PRIME Care study is the largest pharmacogenomic randomized controlled trial in mental health, enrolling 1,944 U.S. Veterans with depression to assess the impact of GeneSight results on treatment outcomes [2][4] - The study found that patients whose clinicians had GeneSight results were significantly more likely to achieve remission over 24 weeks, with a 28% higher likelihood compared to the usual care group [5][6] Group 2: Post-Hoc Analysis Findings - The post-hoc analysis included 1,764 veterans and focused on the time to first remission and response, showing that GeneSight test results increased the rate of remission and response over time [3][6] - Patients who took the GeneSight test were 27% more likely to achieve remission and 21% more likely to experience a significant reduction in depressive symptoms [8] Group 3: GeneSight Test Information - The GeneSight Psychotropic test is a leading pharmacogenomic test for over 60 medications commonly prescribed for mental health conditions, aimed at reducing the trial-and-error process in medication prescribing [7][8] Group 4: Company Background - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, dedicated to advancing health and well-being through molecular tests that guide treatment decisions across various medical specialties [8][9]

Core Points - Evaxion A/S, a clinical-stage TechBio company, will provide a business update and report its Q3 2025 financial results on November 6, 2025 [1] - The company's Executive Management will host a conference call and webcast on the same day at 14:30 CET/08:30 EST, which is open to the public [2] - Evaxion specializes in developing AI-Immunology™ powered vaccines, focusing on immunotherapies for cancer, bacterial diseases, and viral infections [4] Company Overview - Evaxion A/S utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and develop novel immunotherapies [4] - The company has a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting bacterial and viral diseases with high unmet medical needs [4] - Evaxion aims to transform patients' lives by providing innovative and targeted treatment options [4]